for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MYOS RENS Technology Inc

MYOS.OQ

Latest Trade

1.06USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.76

 - 

3.84

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.06
Open
--
Volume
--
3M AVG Volume
31.17
Today's High
--
Today's Low
--
52 Week High
3.84
52 Week Low
0.76
Shares Out (MIL)
12.19
Market Cap (MIL)
14.40
Forward P/E
--
Dividend (Yield %)
--

Next Event

MYOS RENS Technology Inc Extraordinary Shareholders Meeting

Latest Developments

More

Myos Rens Technology Announces Settlement Of Litigation With Rens Technology

MYOS RENS Announces Merger With MedAvail And Spin-Out Of Muscle Health Business

MYOS RENS Launches RACE-Approved Continuing Education Course For Veterinarians

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About MYOS RENS Technology Inc

MYOS RENS Technology Inc. is focused on the discovery, development and commercialization of nutritional ingredients, functional foods, and other technologies for maintaining or improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle-related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement that has been shown in clinical studies to temporarily decrease the levels of serum myostatin, MYO-T12, a formulation containing Fortetropin. Fortetropin is the Company’s all-natural food ingredient clinically shown to enhance muscle size, lean body mass and strength as part of resistance training in humans. Fortetropin is made from fertilized chicken egg yolks using a process that retains the biological integrity and bioactivity of the product.

Industry

Biotechnology & Drugs

Contact Info

45 Horsehill Rd Ste 106

CEDAR KNOLLS, NJ

07927-2009

United States

+1.973.5090444

https://www.myosrens.com/

Executive Leadership

Robert J. Hariri

Independent Chairman of the Board

Joseph Mannello

Chief Executive Officer, Director

Louis J. Aronne

Independent Director

Christopher C. Dewey

Independent Director

Victor E. Mandel

Independent Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
10.68
Price To Book (MRQ)
4.95
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
34.09
LT Debt To Equity (MRQ)
10.96
Return on Investment (TTM)
-111.86
Return on Equity (TTM)
-87.18

Latest News

Latest News

BRIEF-Myos Rens Technology Reports Qtrly Loss Per Share $0.19

* MYOS RENS TECHNOLOGY REPORTS FIRST QUARTER FINANCIAL RESULTS

BRIEF-Joseph Mannello Reports 9.3 Pct Stake In Myos Rens Technology Inc

* JOSEPH MANNELLO REPORTS 9.3 PERCENT STAKE IN MYOS RENS TECHNOLOGY INC AS OF APRIL 27, 2018 - SEC FILING Source text: (https://bit.ly/2FTnvnk) Further company coverage:

BRIEF-David Matlin Reports 8.29 Pct Passive Stake In MYOS RENS Technology As Of April 25, 2018

* DAVID J. MATLIN REPORTS 8.29 PERCENT PASSIVE STAKE IN MYOS RENS TECHNOLOGY AS OF APRIL 25, 2018 - SEC FILING Source text : (https://bit.ly/2rgSl4d) Further company coverage:

BRIEF-Myos Rens Says Qtrly Net Loss Rose 44 Pct To $1.1 MLN

* MYOS RENS TECHNOLOGY REPORTS FOURTH QUARTER AND FISCAL 2017 FINANCIAL RESULTS

BRIEF-Myos Rens Technology Announces Research Agreement With Rutgers University

* MYOS RENS TECHNOLOGY, INC. ANNOUNCES RESEARCH AGREEMENT WITH RUTGERS UNIVERSITY FOCUSED ON DISCOVERY OF COMPOUNDS AND PRODUCTS FOR IMPROVING MUSCLE HEALTH AND PERFORMANCE Source text for Eikon: Further company coverage:

BRIEF-Myos Rens Technology CEO Issues Shareholder Letter

* MYOS RENS TECHNOLOGY CEO ISSUES SHAREHOLDER LETTER Source text for Eikon: Further company coverage:

BRIEF-MYOS RENS Technology reports qtrly loss per share $‍0.13​

* MYOS RENS Technology Inc reports third quarter 2017 financial results

BRIEF-Myos Rens Technology files for mixed shelf of up to $75 mln

* Files for mixed shelf of up to $75 million - sec filing Source text: (http://bit.ly/2z7GifH) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up